Evidence map›Paper›PMID 29793451›Full record

Trial reportBMC psychiatry2018

The effect of financial incentives on patients' motivation for treatment: results of "Money for Medication," a randomised controlled trial.

Ernst L Noordraven, André I Wierdsma, Peter Blanken, Anthony F T Bloemendaal, Cornelis L Mulder

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ernst L NoordravenDual Diagnosis Center Palier, Parnassia Psychiatric Institute, 2552 KS, The Hague, The Netherlands. e.noordraven@erasmusmc.nl.ORCID 0000-0003-4287-7647
André I WierdsmaEpidemiological and Social Psychiatric Research Institute, Department of Psychiatry, Erasmus University Medical Center, 3015 CE, Rotterdam, The Netherlands.
Peter BlankenParnassia Addiction Research Centre (PARC), Brijder Addiction Center, Parnassia Psychiatric Institute, 2553 RJ, The Hague, The Netherlands.
Anthony F T BloemendaalDual Diagnosis Center Palier, Parnassia Psychiatric Institute, 2552 KS, The Hague, The Netherlands.
Cornelis L MulderEpidemiological and Social Psychiatric Research Institute, Department of Psychiatry, Erasmus University Medical Center, 3015 CE, Rotterdam, The Netherlands.
Erasmus MC · NLParnassia Groep · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOffering financial incentives is an effective intervention for improving adherence in patients taking antipsychotic depot medication. We assessed whether patients' motivation for treatment might be reduced after receiving financial rewards.

methodsThis study was part of Money for Medication, a multicentre, open-label, randomised controlled trial, which demonstrated the positive effects of financial incentives on antipsychotic depot compliance. Three mental healthcare institutions in Dutch secondary psychiatric care services participated. Eligible patients were aged 18-65 years, had been diagnosed with schizophrenia or another psychotic disorder, had been prescribed antipsychotic depot medication or had an indication to start using depot medication, and were participating in outpatient treatment. For 12 months, patients were randomly assigned either to treatment as usual (control group) or to treatment as usual plus a financial reward for each depot of medication received (€30 per month if fully compliant; intervention group). They were followed up for 6 months, during which time no monetary rewards were offered for taking antipsychotic medication. To assess treatment motivation after 0, 12 and 18 months, interviews were conducted using a supplement to the Health of the Nation Outcome Scales (HoNOS) and the Treatment Entry Questionnaire (TEQ).

resultsPatients were randomly assigned to the intervention (n = 84) or the control group (n = 85). After 12 months, HoNOS motivation scores were available for 131 patients (78%). Ninety-one percent of the patients had no or mild motivational problems for overall treatment; over time, there were no significant differences between the intervention and control groups. TEQ data was available for a subgroup of patients (n = 61), and showed no significant differences over time between the intervention and control groups for external motivation (β = 0.37 95% CI: -2.49 - 3.23, p = 0.799); introjected motivation (β = - 2.39 95% CI: -6.22 - 1.44, p = 0.222); and identified motivation (β = - 0.91 95% CI: -4.42 - 2.61, p = 0.613). After the 6-month follow-up period, results for the HoNOS and TEQ scores remained comparable.

conclusionsOffering financial incentives for taking antipsychotic depot medication does not reduce patients' motivation for treatment.

trial registrationNetherlands Trial registration, number NTR2350 .

Indexed as

Antipsychotic AgentsMotivationPsychotic DisordersToken EconomyAdultAmbulatory CareDelayed-Action PreparationsFemaleFinancial SupportHumansMaleMedication AdherenceMiddle AgedNetherlandsOutcome Assessment, Health CareSchizophreniaAntipsychotic AgentsDelayed-Action PreparationsAdherenceAntipsychotic depot medicationFinancial incentivesMotivationSchizophrenia

Identifiers

PMID29793451
PMCPMC5968496
OpenAlexW2807575480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.